Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 271

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapy

Open access
Zandberg, Dan P., Algazi, Alain P., Jimeno, Antonio, Good, James S., Fayette, Jérôme, Bouganim, Nathaniel, Ready, Neal E., Clement, Paul M., Even, Caroline, Jang, Raymond W., Wong, Stuart, Keilholz, Ulrich, Gilbert, Jill, Fenton, Moon, Braña, Irene, Henry, Stephanie, Remenar, Eva, Papai, Zsuzsanna, Siu, Lillian L., Jarkowski, Anthony, Armstrong, Jon M., Asubonteng, Kobby, Fan, Jean, Melillo, Giovanni, Mesía, Ricard · 2019 · European Journal of Cancer

Abstract

BACKGROUND: Patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) progressing on platinum-based chemotherapy have poor prognoses and limited therapeutic options. Programmed cell death-1 (PD-1) and its ligand 1 (PD-L1) are frequently upregulated in HNSCC. The international, multi-institutional, single-arm, phase II HAWK study (NCT02207530) evaluated durvalumab monotherapy, an anti-PD-L1 monoclonal antibody, in PD-L1-high patients with platinum-refractory R/M HNSCC. PATIENTS AND METHODS: Immunotherapy-naïve patients with confirmed PD-L1-high tumour cell expression (defined as patients with ≥25% of tumour cells expressing PD-L1 [TC ≥ 25%] using the VENTANA PD-L1 [SP263] Assay) received durvalumab 10 mg/kg intravenously every 2 weeks for up to 12 months. The primary end-point was objective response rate; secondary end-points included progression-free survival (PFS) and overall survival (OS). RESULTS: Among evaluable patients (n = 111), objective response rate was 16.2% (95% confidence interval [CI], 9.9-24.4); 29.4% (95% CI, 15.1-47.5) for human papillomavirus (HPV)-positive patients and 10.9% (95% CI, 4.5-21.3) for HPV-negative patients. Median PFS and OS for treated patients (n = 112) was 2.1 months (95% CI, 1.9-3.7) and 7.1 months (95% CI, 4.9-9.9); PFS and OS at 12 months were 14.6% (95% CI, 8.5-22.1) and 33.6% (95% CI, 24.8-42.7). Treatment-related adverse events were 57.1% (any grade) and 8.0% (grade ≥3); none led to death. At data cut-off, 24.1% of patients remained on treatment or in follow-up. CONCLUSION: Durvalumab demonstrated antitumour activity with acceptable safety in PD-L1-high patients with R/M HNSCC, supporting its ongoing evaluation in phase III trials in first- and second-line settings. In an ad hoc analysis, HPV-positive patients had a numerically higher response rate and survival than HPV-negative patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.ejca.2018.11.015

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Research works printed but not linked: 3

  1. Leon, 2005, A retrospective analysis of the outcome of patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck refractory to a platinum-based chemotherapy, Clin Oncol (R Coll Radiol), 17, 418, 10.1016/j.clon.2005.02.014 · doi:10.1016/j.clon.2005.02.014
  2. Zenda, 2007, Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN), Jpn J Clin Oncol, 37, 477, 10.1093/jjco/hym059 · doi:10.1093/jjco/hym059
  3. Chau, 2016, Analysis of immune infiltrates in a genomically characterized clinical cohort of head and neck squamous cell carcinoma (HNSCC) patients (pts), J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.6052 · doi:10.1200/jco.2016.34.15_suppl.6052

Cited by

Metadata

Authors
Zandberg, D. P., Algazi, A. P., Jimeno, A., Good, J. S., Fayette, J., Bouganim, N., Ready, N. E., Clement, P. M., Even, C., Jang, R. W., Wong, S., Keilholz, U., Gilbert, J., Fenton, M., Braña, I., Henry, S., Remenar, E., Papai, Z., Siu, L. L., Jarkowski, A., Armstrong, J. M., Asubonteng, K., Fan, J., Melillo, G., & Mesía, R.
Venue
European Journal of Cancer
Publisher
Elsevier BV
Published
2019-01
Volume
107
Pages
142-152
ISSN
0959-8049 (ISSN-L)
OpenAlex
W2905201605
Cited by
271
References
13
FWCI
9.18
Type
journal article
Language
en
Open access
hybrid
Licence
Funders
AstraZeneca

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.